

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): January 10, 2022

QUANTUM-SI INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

001-39486
(Commission File Number)

85-1388175
(IRS Employer
Identification No.)

**530 Old Whitfield Street
Guilford, Connecticut**
(Address of principal executive offices)

06437
(Zip Code)

Registrant's telephone number, including area code: **(203) 458-7100**

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading Symbol(s)</u>	<u>Name of each exchange on which registered</u>
Class A common stock, par value \$0.0001 per share	QSI	The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of \$11.50 per share	QSI AW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On January 10, 2022, Quantum-Si Incorporated issued a press release announcing that its management will discuss certain business updates at the 40th Annual J.P. Morgan Healthcare Conference. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

- (d) Exhibits.

**Exhibit
No.****Description**

[99.1](#)
104

Press Release of Quantum-Si Incorporated dated January 10, 2022.
Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

QUANTUM-SI INCORPORATED

By: /s/ John Stark

Name: John Stark

Title: Chief Executive Officer

Date: January 10, 2022



Quantum-Si Provides Business Updates at the 40th Annual J.P. Morgan Healthcare Conference

GUILFORD, Conn., Jan. 10, 2022 -- (BUSINESS WIRE) -- [Quantum-Si Incorporated](#) (Nasdaq: QSI) (“Quantum-Si,” or the “Company”), a life sciences tools company commercializing a single molecule protein sequencing platform, today announced that management will discuss the following business updates at the 40th Annual J.P. Morgan Healthcare Conference.

Commercial update

- Quantum-Si has established list prices for its end-to-end protein sequencing platform as follows:
 - o \$70,000 for the PlatinumTM Single Molecule Analyzer
 - o \$20,000 for the CarbonTM automated sample preparation instrument
 - o Company will begin taking pre-orders in the 1st half of 2022 for delivery at full commercial release.

Technology update

- Quantum-Si posted its first technical manuscript on [bioRxiv](#). The manuscript, titled “Real-time dynamic single-molecule protein sequencing on an integrated semiconductor device,” provides a detailed overview of Time Domain SequencingTM enabling massively-parallel single molecule protein sequencing at individual amino acid resolution on a semiconductor chip.
- Updates on the progress with External Early Access Partners

Insight into 2022 Company Strategic Focus

Since completing its [business combination with HighCape Capital Acquisition Corp on June 10, 2021](#), Quantum-Si has successfully launched its early access program, strengthened its management team and board of directors, and expanded its infrastructure to support commercialization and growth over the coming years.

“The Company entered a tremendous growth phase in 2021 enabled by the capital raised taking the company public with expansion of the team across all areas of the Company,” said John Stark, Chief Executive Officer of Quantum-Si. “We look forward to discussing our progress and building upon our strong momentum as we continue our commercialization path in 2022.”

Webcast Information

To access the live webcast of Quantum-Si’s virtual presentation at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 4:30 pm ET, please use the webcast link available in the [Events & Presentations](#) section of the Quantum-Si investor website. A replay of the webcast will be available for a limited period following the conference.

About Quantum-Si Incorporated

Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single molecule next-generation protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's shares of Class A common stock on The Nasdaq Stock Market LLC; the ability to recognize the anticipated benefits of the recently completed business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the potential attributes and benefits of the Company's products and services; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development and commercialization of products and services that the Company is developing; the size and growth potential of the markets for the Company's future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services following anticipated commercial launch; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

###

Investor Contacts

Juan Avendano

Mike Cavanaugh

(617) 877-9641

ir@quantum-si.com

Media Contact

Cammy Duong

(203) 682-8380

QSI-PR@westwicke.com

Source: Quantum-Si Incorporated
